Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Novo Nordisk, Valo Health expand drug discovery collaboration
- Standard BioTools announces publication on study using SomaScan Platform
- Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone
- Novo Nordisk Poised for Short-Term Gains, while Eli Lilly Promises Stronger Long-Term Growth